Welcome to our dedicated page for Trident Brands news (Ticker: TDNT), a resource for investors and traders seeking the latest updates and insights on Trident Brands stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Trident Brands's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Trident Brands's position in the market.
Trident Brands Incorporated (OTCQB: TDNT) plans to issue 29,320,432 shares of Preferred Stock to satisfy approximately $17.7 million in principal and accrued interest owed under convertible notes. This move, approved by shareholders and filed on March 31, 2022, aims to restructure the company's balance sheet, facilitating its strategic plans. The conversion will occur at a rate of $0.60 per share, with the amendment taking effect on May 31, 2022, following SEC filings. CEO Michael Friedman emphasized the importance of this restructuring for future growth.
Trident Brands Inc. (OTCQB: TDNT) announced the publication of a study showing positive effects from its Brain Armor® neuro-nutrition supplements for traumatic brain injury (TBI). The research indicates that dietary supplementation with docosahexaenoic acid (DHA) reduces neuroinflammation markers after TBI. In a preclinical model, DHA outperformed alternatives like cannabidiol. The findings suggest that prophylactic supplementation could be crucial for individuals at risk of concussions, particularly in sports and military contexts. Further research is encouraged to explore treatment possibilities.
FAQ
What is the market cap of Trident Brands (TDNT)?
